This is supported by the recent siRNA knockdown of the ALAS1 mRNA showing effective prevention of adverse effects from acute hepatic porphyrias46,47, pointing to a similar therapeutic benefit of ALAS2 inhibition for porphyrias in the erythropoietic pathway. This evidence concerns the gene ALAS2 and porphyria.